CEO sees Dr. Strack's expertise as vital for the advancement...
CEO sees Dr. Strack's expertise as vital for the advancement of cadisegliatin's phase 3 study. Dr. Strack is optimistic about its potential, especially with its Breakthrough Therapy Designation from the FDA.
Press Release: VTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3440Followers
0Following
8254Visitors
Follow